

## **Additional File 2**

### **Serological Assessment of Neutrophil Elastase Activity during Lung ECM Remodeling**

<sup>£12</sup>Jacob H. Kristensen, <sup>1</sup>Morten A. Karsdal, <sup>1</sup>Jannie M.B. Sand, <sup>1</sup>Nicholas Willumsen, Claudia Diefenbach<sup>3</sup>, Birte Svensson, Per Hägglund, <sup>1</sup>Diana J. Oersnes-Leeming

<sup>£</sup>Corresponding author: Jacob H. Kristensen [jhk@nordicbioscience.com](mailto:jhk@nordicbioscience.com)

<sup>1</sup>Nordic Bioscience A/S, Herlev, Denmark

<sup>2</sup>The Technical University of Denmark, Department of Systems Biology, Denmark

<sup>3</sup>Boehringer-Ingelheim Pharma GmbH, Biberach, Germany

## **Contents**

### **Appendix 1:**

**Table S1: Patient Demographics and Clinical Profiles of Cancer and IPF Patients**

## **Appendix 1**

.

Group	n	Gender, % females	Tumor stage (n)				Smoking status			Age, mean $\pm$ SD (range)
			I	II	III	IV	never	ever	unknown	
Lung cancer, all	40	25%	13	12	12	3	3	35	2	59 $\pm$ 10 (46-82)
SCLC	8	25%	2	1	4	1	-	7	1	61 $\pm$ 12 (46-82)
NSCLC	32	25%	11	11	8	2	3	28	1	60 $\pm$ 9 (46-80)
<i>Adenocarcinoma</i>	16	37.50%	4	6	6	-	-	15	1	57 $\pm$ 10 (46-80)
<i>Squamous cell carcinoma</i>	16	12.50%	7	5	2	2	3	13	-	63 $\pm$ 6 (53-73)
IPF (FEV 63-68 %)	10	20%	-	-	-	-	9	1	-	74 $\pm$ 5 (67-83)

Table S1: Patient Demographics and Clinical Profiles of Cancer and IPF Patients. Abbreviations: FEV, forced expiratory volume; IPF, idiopathic pulmonary fibrosis; NSCLC, non-small-cell lung carcinoma; SCLC, small cell lung carcinoma.